CI vs HNGE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CI is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CI and HNGE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CI and HNGE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

The Cigna Group is a large US health-services company built around two main engines. Its Evernorth health-services arm includes Express Scripts, one of the largest pharmacy benefit managers (PBMs) in the country, plus specialty pharmacy, care services, and pharmacy-related businesses; this is now the larger revenue and growth driver. Its Cigna Healthcare arm sells commercial health insurance, primarily to employers and individuals, along with international and supplemental coverage. Cigna makes money by collecting insurance premiums and managing medical costs, and by earning fees and spreads on managing drug benefits, negotiating with manufacturers, and dispensing specialty medications at scale. After exiting most of its Medicare businesses, Cigna is increasingly weighted toward commercial insurance and pharmacy services rather than government programs. It is headquartered in Bloomfield, Connecticut, and serves employers, health plans, government entities, and individuals.

Full CI guide

Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. The company's core offering combines a mobile and connected-sensor app with personalized exercise therapy programs, behavioral health support, and access to physical therapists, plus care navigation for surgery decisions. Customers are primarily large employers and health plans that purchase Hinge Health benefits for their members.

Full HNGE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CI drivers: Evernorth and pharmacy services scale; Stable commercial insurance core.
• HNGE drivers: Employer benefit penetration; Surgery prevention as ROI driver.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Cigna faces significant regulatory and political risk: PBMs are under scrutiny from Congress, the FTC, and states over drug-pricing practices and rebate models, and potential reform could pressure the economics of Express Scripts. For HNGE, digital health categories are competitive with various platforms targeting MSK and other condition areas, including the well-funded private Sword Health.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CI if you believe its drivers more; HNGE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CI and HNGE guides.

CI. Cigna trades near 12.5 times trailing GAAP earnings and about 9 times analysts' 2027 adjusted estimate, a discount to the broad market that reflects PBM regulatory risk and the optically huge but low-margin pharmacy pass-through revenue. The bull case leans on steady adjusted EPS beats (four quarters running), about $8 billion of annual free cash flow and heavy buybacks; the discount is the market pricing in policy and drug-pricing uncertainty. Third-quarter results arrive November 5, 2026.

HNGE. Hinge Health's valuation has moved from a story about reaching profitability to one about sustaining fast, profitable growth. At about 33x trailing and forward earnings and 11x sales after a ~123% year-to-date gain, the shares sit just below the ~$112 average analyst target, so the November 2 third-quarter report (consensus ~$0.60 EPS on ~$224.8 million of revenue) will be read for whether growth near 50% can hold.

Headline figures (approximate, October 2026): CI shows revenue (ttm) ~$282 billion (inflated by pharmacy pass-through revenue); Q2 2026 ~$71.7 billion, net income (ttm) ~$6.4 billion; ~2.3% net margin, ~4% operating margin, adjusted eps Q2 2026 $7.78 vs ~$7.60 expected; 2026 consensus ~$30.51, 2027 ~$33.48, p/e ~12.5x trailing GAAP; ~9x on 2027 consensus; HNGE shows revenue (ttm) ~$720 million; Q2 2026 ~$212.8 million, up ~53% year over year, gross / operating margin ~85% / ~19%, net income (ttm) ~$107 million (Q2 2026 ~$43.1 million), adjusted eps (q2 2026) ~$0.59 vs ~$0.62 estimate.

CI and HNGE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CI and HNGE exposure against your real portfolio. It is not an investment adviser.